Sanofi-Aventis SA
SNY (NYSE)
Forecast has expired
Ended: Tuesday January 2, 2007
Target
$55.30 and above
$8.00 (16.9%)
Time Span:3-6mths
Final
$30.52
-$16.78 (35.5%)
Recommendation
Rating:Buy
Risk:Moderate
Stop Loss Price:$43.00
Final XP:
0
Target not reached
Analysis
Watch carefully regarding news for acomplia. If FDA does not approve then there may be a negative effect on the price. FDA Approval for Acomplia Acomplia received it initial approval from the FDA with condition and Sanofi-Aventis is working to meet these requirements. The Drug was estimated to be release this year and right now is under a slight delay. I think Acomplia should be ready for the market by the end of this year and should have an uplifting effect for the stock price as there is already high anticipation by the public for its release. Currently no news out regarding its official launch date. http://www.foxnews.com/story/0,2933,184870,00.html